Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

DISMEVAL · Developing and validating disease management evaluation methods for European health care systems

FP7Status: CLOSED1 January 200931 December 2011EU funding €2,651,891

Chronic health conditions that impose a heavy burden on society and account for a large share of health care costs. Better prevention and management could potentially decrease costs and improve quality of care and health outcomes. An important means of accomplishing these goals is through the use of disease management (DM) interventions that educate patients about prevention and health management strategies, while also providing guidance, behavioral modification techniques, and social and emotional support. DM also seeks to assist providers by informing them about best practices and treatment opportunities. The underlying assumption is that DM leads to better quality of care, more health-conscious behavior, and improved disease prevention and control. In the short run, disease management would decrease costs by optimizing utilization of medical care. In the long run, DM lead to improved health status among patients with chronic conditions, thereby avoiding medical expenditures and improving workplace productivity. Many health care systems in Europe and elsewhere are beginning to embrace DM programmes. Although the concept of disease management offers great promise, these programs’ ability to reduce cost and improve care has not yet been empirically demonstrated; more and more policymakers are demanding objective assessments of a programme’s impact. Part of the problem is that there are no universally accepted evaluation methods to measure and report programme performance in a scientifically sound fashion that is also practicable for routine operations. This project seeks to bridge this gap. It will provide an overview of approaches to chronic care and DM methods across Europe and test and validate possible evaluation approaches. These include non-experimental and experimental evaluation designs and performance measures. Best practices will be identified and used to develop recommendations for policymakers, program operators and researchers.

Consortium · 10 organisations

coordinator

RAND EUROPE COMMUNITY INTEREST COMPANY

UK · €937,328

participant

INSTITUTO DE SALUD CARLOS III

ES · €184,154

participant

CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD

FR · €44,280

participant

KOBENHAVNS UNIVERSITET

DK · €187,136

participant

UNIVERSITEIT MAASTRICHT

NL · €407,723

participant

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

UK · €97,204

participant

AQUA-INSTITUT FUR ANGEWANDTE QUALITATSFORDERUNG UND FORSCHUNG IM GESUNDHEITSWESEN GMBH

DE · €139,964

participant

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN

DE · €194,578

participant

UNIVERSITE PARIS XII VAL DE MARNE

FR · €201,360

participant

PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG

AT · €258,164

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.